Suppr超能文献

评价可乐定抑制试验在嗜铬细胞瘤诊断中的价值。

Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma.

机构信息

Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, Northern Ireland, UK.

出版信息

J Hum Hypertens. 2011 Jul;25(7):451-6. doi: 10.1038/jhh.2010.78. Epub 2010 Sep 2.

Abstract

The aim of this study is to review the experience of the clonidine suppression test in a regional endocrine centre and to compare the diagnostic sensitivity and specificity using various previous published criteria. The design used is retrospective study. The subjects include 56 patients in whom clonidine suppression tests had been performed from 1995 to 2000: 15 with phaeochromocytoma and 41 patients in whom the diagnosis was excluded using a combination of biochemical testing, abdominal computed tomography scanning and clinical follow-up. Plasma catecholamines were measured by high pressure liquid chromatography on basal samples and at hourly intervals for 3 h after the administration of clonidine 300 μg orally and the following diagnostic criteria were applied: plasma noradrenaline+adrenaline>2.96 nmol l(-1) at 3 h post-clonidine or a baseline plasma adrenaline plus noradrenaline>11.82 nmol l(-1); plasma noradrenaline>2.96 nmol l(-1) at 3 h post-clonidine and plasma noradrenaline>2.96 nmol l(-1) and <50% fall in noradrenaline at 3 h post-clonidine. The results obtained is that mean plasma noradrenaline plus adrenaline fell across the test in 40/41 patients in the non-phaeochromocytoma patients and was lowest at 3 h (basal 2.28 ± 0.14 vs 1.36 ± 0.11 nmol l(-1), P<0.001). In the phaeochromocytoma group, clonidine had a variable effect on adrenaline plus noradrenaline levels with increases in 7/15. Using an abnormal result as a 3 h level of noradrenaline plus adrenaline>2.96 mmol l(-1) gave a sensitivity of 93% and specificity of 95%. When a 3 h noradrenaline>2.96 mmol l(-1) was used, sensitivity was 87% and specificity 95%. Using the former criteria, noradrenaline plus adrenaline>2.96 mmol l(-1), 1/15 in the phaeochromocytoma group had a normal result after clonidine suppression testing. Two of 41 in the non-phaeochromocytoma group had a false-positive result. Under carefully controlled conditions, the clonidine suppression test is well tolerated, safe and accurate for use in the investigation of patients with suspected phaeochromocytoma.

摘要

本研究旨在回顾一个区域性内分泌中心的可乐定抑制试验经验,并使用各种先前发表的标准比较诊断的敏感性和特异性。所采用的设计是回顾性研究。研究对象包括 1995 年至 2000 年间进行可乐定抑制试验的 56 例患者:15 例为嗜铬细胞瘤患者,41 例患者通过生化检测、腹部计算机断层扫描和临床随访相结合排除诊断。在给予可乐定 300μg 口服后,使用高效液相色谱法测定基础样本和 3 小时内每小时的血浆儿茶酚胺,应用以下诊断标准:可乐定后 3 小时血浆去甲肾上腺素+肾上腺素>2.96nmol/L,或基线时血浆肾上腺素+去甲肾上腺素>11.82nmol/L;可乐定后 3 小时血浆去甲肾上腺素>2.96nmol/L,可乐定后 3 小时血浆去甲肾上腺素>2.96nmol/L,且去甲肾上腺素下降<50%。结果显示,41 例非嗜铬细胞瘤患者的试验中平均血浆去甲肾上腺素+肾上腺素在整个试验中下降,且在 3 小时时最低(基础值 2.28±0.14 vs 1.36±0.11nmol/L,P<0.001)。在嗜铬细胞瘤组中,可乐定对肾上腺素+去甲肾上腺素水平的影响不同,15 例中有 7 例增加。将异常结果定义为 3 小时去甲肾上腺素+肾上腺素>2.96mmol/L 时,敏感性为 93%,特异性为 95%。当使用 3 小时去甲肾上腺素>2.96mmol/L 时,敏感性为 87%,特异性为 95%。使用前一标准,即去甲肾上腺素+肾上腺素>2.96mmol/L,嗜铬细胞瘤组中 1/15 的患者在可乐定抑制试验后结果正常。41 例非嗜铬细胞瘤组中有 2 例出现假阳性结果。在严格控制的条件下,可乐定抑制试验耐受性良好,安全准确,可用于疑似嗜铬细胞瘤患者的检查。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验